Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Convertible Debt (2016 - 2018)

Historic Convertible Debt for Viking Therapeutics (VKTX) over the last 5 years, with Q1 2018 value amounting to $1.5 million.

  • Viking Therapeutics' Convertible Debt fell 5960.17% to $1.5 million in Q1 2018 from the same period last year, while for Mar 2018 it was $1.5 million, marking a year-over-year decrease of 5960.17%. This contributed to the annual value of $1.5 million for FY2017, which is 0.0% changed from last year.
  • Viking Therapeutics' Convertible Debt amounted to $1.5 million in Q1 2018, which was down 5960.17% from $1.5 million recorded in Q4 2017.
  • Viking Therapeutics' 5-year Convertible Debt high stood at $3.7 million for Q1 2017, and its period low was $1.3 million during Q4 2014.
  • In the last 5 years, Viking Therapeutics' Convertible Debt had a median value of $1.5 million in 2016 and averaged $1.8 million.
  • In the last 5 years, Viking Therapeutics' Convertible Debt skyrocketed by 11957.18% in 2016 and then tumbled by 5960.17% in 2018.
  • Quarter analysis of 5 years shows Viking Therapeutics' Convertible Debt stood at $1.3 million in 2014, then skyrocketed by 70.2% to $2.2 million in 2015, then plummeted by 30.28% to $1.5 million in 2016, then changed by 0.0% to $1.5 million in 2017, then changed by 0.0% to $1.5 million in 2018.
  • Its Convertible Debt was $1.5 million in Q1 2018, compared to $1.5 million in Q4 2017 and $1.5 million in Q3 2017.